BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,139,926 | +552852.5% | 81,150 | +248.0% | 0.02% | +250.0% |
Q1 2023 | $387 | -31.9% | 23,321 | -68.7% | 0.01% | -45.5% |
Q4 2022 | $568 | -99.9% | 74,508 | -6.5% | 0.01% | -35.3% |
Q3 2022 | $792,000 | -60.6% | 79,726 | -33.8% | 0.02% | -50.0% |
Q4 2021 | $2,008,000 | -52.8% | 120,372 | +32.7% | 0.03% | -50.7% |
Q3 2021 | $4,251,000 | +48.2% | 90,693 | +92.7% | 0.07% | +27.8% |
Q2 2021 | $2,869,000 | – | 47,063 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |